Illumina Inc. Stock
€93.62
Your prediction
Illumina Inc. Stock
Pros and Cons of Illumina Inc. in the next few years
Pros
Cons
Performance of Illumina Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Illumina Inc. | -0.540% | 8.395% | 16.153% | -16.210% | -26.974% | -55.599% | -71.232% |
| Veeva Systems A | -0.200% | 2.389% | 2.727% | 40.373% | 22.343% | 13.646% | 12.795% |
| Thermo Fisher Scientific Inc. | -0.430% | 14.851% | 19.742% | -25.202% | -16.371% | -28.701% | 20.190% |
| Waters Corp. | 1.150% | 7.403% | -12.786% | -11.672% | -26.153% | -26.288% | 42.717% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Given a brief glance, Illumina with the US symbol (ILMN) seemingly presents an interesting financial scenario. There exist varied factors in the financials that catch attention, while certain aspects bespeak areas the company needs to address. However, it is important to delve deeper into the data for a comprehensive understanding.
The gross profit as per the Trailing Twelve Months (TTM) indicates a prospect reassuringly. The GrossProfitTTM is 3145000000, referring to overall revenue's percentage that the company retains after direct costs associated with making the products have been considered. Maintaining a healthy gross margin suggests productive internal cost management and pricing policies compared to competitors.
In terms of the company's market appeal indicated by the Price-to-Sales (PriceSalesTTM: 6.6241) and Price-to-Book (PriceBookMRQ: 4.8854) ratios. Both are less than the commonly used threshold of 10 for overvalued prospects, indicating a potentially undervalued situation assuming sustained performance. Thus, for investors keen on value investing, Illumina could be an interesting opportunity.
Comments
News
Illumina Stock: Shares Hit New Low Despite Growth Plans
Illumina's stock has plummeted to a 52-week low of $94.72, marking a significant 28% decline from the previous year, despite the biotechnology company's robust annual revenue of $4.37 billion and
Why Illumina Stock Got Mashed on Monday
On Monday, for the second time in as many business days, Illumina (NASDAQ: ILMN) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost
Why Illumina Stock Is Sinking Today
Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time, the S&P